First 20 years with recombinant FVIIa (NovoSeven)

Haemophilia

Volumn 17, Issue 1, 2011, Pages

  Hedner, U ^a   Lee, C A ^b,c  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c Oxford Haemophilia and Thrombosis Centre   (United Kingdom)

Author keywords

Haemophilia; Haemostasis; Recombinant FVIIa

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 5A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 BYPASSING ACTIVITY; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 CONCENTRATE; CYCLOPHOSPHAMIDE; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; STEROID; THROMBIN; UNCLASSIFIED DRUG;

ARTERY THROMBOSIS; ARTHROPATHY; BLEEDING TIME; BLOOD CLOTTING; CONTINUOUS INFUSION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; ELECTIVE SURGERY; HEMARTHROSIS; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HEMOPHILIC ARTHROPATHY; HEMOSTASIS; HOME CARE; HUMAN; IMMUNOLOGICAL TOLERANCE; LOW DRUG DOSE; MUSCLE BLEEDING; NONHUMAN; ORTHOPEDIC SURGERY; PRIORITY JOURNAL; PROTHROMBIN TIME; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; REVIEW; ROOM TEMPERATURE; THROMBIN TIME; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM; THROMBOPHLEBITIS; VEIN THROMBOSIS;

FACTOR VIIA; HEMOPHILIA A; HEMOPHILIA B; HEMORRHAGE; HEMOSTASIS; HUMANS; RECOMBINANT PROTEINS;

EID: 79951933686     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02352.x     Document Type: Review

References (85)

1. Ahlberg Å. Haemophilia in Sweden VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand 1965; 77(Suppl.): 7-80.
2. Nilsson IM, Blombäck M, Ahlberg Å. Our Experience in Sweden with prophylaxis on haemophilia. Proc 5th Congr Wld Fed Hemophilia, Montreal 1968; Bibl Haematol 1970; 34: 111-24.
3. Nilsson IM, Hedner U, Björlin G. Suppression of factor IX antibody in hemophilia B by factor IX and cyclophosphamide. Ann Intern Med 1973; 78: 91-5.
4. Fekete LF, Holst SL, Peetoom F, DE Veber LL. "Auto" factor IX Concentrate: A New Therapeutic Approach To Treatment of Hemophilia A Patients With Inhibitors. San Paulo, Brasil: XIV Congresso Internacional de Hamatologia, 26-21 de Jul, 1972. Abstr #295.
5. Kurczynski EM, Penner JA. Activated prothrombin concentrate for patients with factor VIII inhibitors. New Engl J Med 1974; 291: 164-7.
6. Penner JA, Kelly PE. Management of patients with factor VIII or IX inhibitors. Semin Thromb Hemost 1975; 1: 386-99.
7. Kelly PE, Penner JA. Antihemophilic factor inhibitor: management with prothrombin complex concentrates. JAMA 1974; 291: 164-7.
8. Preston FE, Dinsdale RCW, Sucliff DJ, Bardhan G, Wyld PJ, Hamly JF. Factor VIII inhibitor bypassing activity (FEIBA) in the management of patients with factor VIII inhibitors. Thromb Res 1977; 11: 643-51.
9. Price DA, d'Souza S, Ekert H. The use of non-activated prothrombin concentrate in the management of haemophilia A with factor VIII antibodies. Austr NZ J Med 1977; 7: 286-90.
10. Blatt PM, Ménache D, Roberts H. A survey of the effectiveness of prothrombin complex concentrates in controlling hemorrhage in patients with hemophilia and anti-factor VIII antibodies. Thromb Haemost 1981; 45: 39-42.
11. Vinazzer H. Comparison between two concentrates with factor VIII inhibitor bypassing activity. Thromb Res 1982; 26: 21-9.
12. Penner JA. Treatment of inhibitor patients with activated prothrombin complex concentrates. In: Hoyer L ed. Factor VIII Inhibitors. New York, NY: Alan R. Liss, Inc., 1984: 291-308.
13. Lusher JM, Shapiro SS, Palascak JE et al. Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII. New Engl J Med 1980; 303: 421-5.
14. Sjamsoedin LJM, Heijnen L, Mauser-Bunschoten EP et al. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. New Engl J Med 1981; 305: 717-21.
15. Lusher JM, Blatt PM, Penner JA et al. Autoplex versus Proplex: a controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII. Blood 1983; 62: 1135-8.
16. Young G, Shafer FE, Rojas P, Seremetis S. Single 270 ug/kg-dose rFVIIa vs. standard 90 ug/kg-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia 2008; 14: 287-94.
17. Stenbjerg S, Jørgensen J. Activated FIX concentrate (FEIBA) used in the treatment of haemophilic patients with antibody to FVIII. Acta Med Scand 1978; 203: 471-6.
18. Hilgartner MW, Knatterud GL and the FEIBA Study Group. The use of factor eight inhibitor by-passing activity (FEIBA Immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood 1983; 61: 36-40.
19. Kasper CK, Feinstein DI. Rising factor VIII inhibitor titers after Konyne Factor IX complex. New Engl J Med 1976; 295: 505 (letter).
20. Steinberg MH, Dreiling BJ. Vascular lesions in hemophilia B. N Engl J Med 1973; 289: 592.
21. Blatt PM, Lundblad RL, Kingdon HS, McLean G, Roberts HR. Thrombogenic materials in prothrombin complex concentrates. Ann Intern Med 1974; 81: 766-70.
22. Kasper CK. Postoperative thrombosis in hemophilia B. N Engl J Med 1973; 289: 160.
23. Kasper CK. Thromboembolic complications. Thromb Diath Haemorrh 1975; 33: 640-4.
24. Marchesi SL, Burney R. Prothrombin-complex concentrates and thromboses. N Engl J Med 1974; 290: 403-4.
25. Tullis JL, Melin M, Jurigian P. Clinical use of human prothrombin complexes. N Engl J Med 1965; 273: 667-74.
26. Edson JR. Prothrombin-complex concentrates and thromboses. N Engl J Med 1974; 290: 403.
27. Cederbaum AI, Blatt PM, Roberts HR. Intravascular coagulation associated with the use of human prothrombin complex. Ann Intern Med 1976; 84: 683-7.
28. Davey RJ, Shashaty GG, Rath CE. Acute coagulopathy following infusion of prothrombin complex concentrates. Am J Med 1976; 60: 719-22.
29. Schimpf KL, Zimmerman K, Kompf B. DIC and postoperative wound bleeding under factor IX substitution therapy in a case of hemophilia B: successful treatment with heparin. Thromb Res 1976; 8: 65-70.
30. Kingdon HS, Lundblad RL, Veltkamp JJ, Aronson DL. Potentially thrombogenic materials in factor IX concentrates. Thromb Diath Haemorrh 1975; 33: 617-31.
31. Ratnoff OD. Prothrombin complex preparations: a cautionary note. Ann Intern Med 1974; 81: 852.
32. Blajchman MA, Vamvakas EC. The continuing risk of transfusion-transmitted infections. N Engl J Med 2006; 355: 1303-5.
33. Nilsson IM, Hedner U, Holmberg L. Suppression of factor VIII antibody by combined factor VIII and cyclophosphamide. Acta Med Scand 1974; 195: 65-72.
34. Morfini M, Haya S, Tagariello G et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007; 13: 606-12.
35. Hedner U, Nilsson IM, Bergentz S-E. Various prothrombin complex concentrates and their effect on coagulation and fibrinolysis in vivo. Thromb Haemostas 1976; 35: 386-95.
36. Hedner U, Nilsson IM, Bergentz S-E. Studies on thrombogenic activities in two prothrombin complex concentrates. Thromb Haemost 1979; 42: 1022-32.
37. White GC II, Roberts HR, Kingdon HS. Prothrombin complex concentrates: potentially thrombogenic materials and clues to the mechanism of thrombosis in vivo. Blood 1977; 49: 159-70.
38. Østerud B, Miller-Andersson M, Abildgaard U, Prydz H. The effect of antithrombin III on the activity of the coagulation factors VII, IX and X. Thromb Haemost 1976; 35: 295-304.
39. Hedner U, Kisiel W. Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. J Clin Invest 1983; 71: 1836-41.
40. Hedner U, Bjoern S, Bernvil SS, Tengborn L, Stigendahl L. Clinical experience with human plasma-derived factor VIIa in patients with hemophilia A and high titer inhibitors. Haemostasis 1989; 19: 335-43.
41. Jurlander B, Thim L, Klausen NK et al. Recombinant activated factor VII (rFVIIa): characterization, manufacturing, and clinical development. Semin Thromb Hemost 2001; 27: 373-83.
42. Hedner U. Factor VIIa in the treatment of haemophilia. Blood Coagul Fibrinolysis 1990; 1: 307-17.
43. Diness V. rFVIIa in an endotoxin model and in a Wessler model. In: Hedner U, Roberts HR eds. Proceedings 2nd Symposium on New Aspects of Hemophilia Treatment. The Netherlands: Medicon Europe, Bussum, 1991: 147-50.
44. Hedner U, Schulman S, Alberts KA et al. Successful use of rFVIIa in a patient with hemophilia A subjected to synovectomy. Lancet 1988; II: 1193.
45. Hedner U, Ingerslev J. Clinical use of recombinant FVIIa (rFVIIa). Transfus Sci 1998; 19: 163-76.
46. Lusher J, Ingerslev J, Roberts HR, Hedner U. Clinical experience with recombinant factor VIIa. A review. Blood Coagul Fibrinolysis 1998; 9: 119-28.
47. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80: 773-8.
48. Ludlam CA, Smith MP, Morfini M, Gringeri A, Santagostino E, Savidge GF. A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation. Br J Haematol 2003; 120: 808-13.
49. Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002; 22: 1381-9.
50. Østerud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977; 74: 5260-4.
51. Repke D, Gemmell CH, Guha A, Turitto VT, Broze G, Nemerson Y. Hemophilia as a defect of the tissue factor pathway of blood coagulation: effect of factors VIII and IX on factor X activation in a continuous-flow reactor. Proc Natl Acad Sci USA 1990; 87: 7623-7.
52. Rapaport SI. The activation of factor IX by the tissue factor pathway. Prog Clin Biol Res 1981; 72: 57-76.
53. Rapaport SI, Rao LVM. The tissue factor pathway: how it has become a "Prima Ballerina". Thromb Haemost 1995; 74: 7-17.
54. Roberts HR, Monroe DM, Hoffman M. Molecular biology and biochemistry of the coagulation factors and pathways of hemostasis. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U eds. Williams Hematology. 6th edn, Chapter 112. New York: The McGraw-Hill Companies, Inc, 2001: 1409-34.
55. Hedner U, Lund-Hansen T, Winther D. Comparison of the effect of factor VII prepared from human plasma (pVIIa) and recombinant VIIa (rVIIa) in vitro and in rabbits. Thromb Haemost 1987; 58: 270. Abstr #989.
56. Hedner U. Factor VIIa and its potential therapeutic use in bleeding-associated pathologies. Thromb Haemost 2008; 100: 557-62.
57. Brinkhous KM, Hedner U, Garris JB, Diness V, Read MS. Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia, hemophilia B, and von Willebrand disease. Proc Natl Acad Sci USA 1989; 86: 1382-6.
58. Key NS, Aledort LM, Beardsley D et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (NovoSeven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912-8.
59. Cooper HA, Jones CP, Campion E, Roberts HR, Hedner U. Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures. Haemophilia 2001; 7: 517-22.
60. Kavakli K, Makris M, Zulfikar B et al. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. Thromb Haemost 2006; 95: 600-5.
61. Kenet G, Stenmo CB, Blemings A et al. Intra subject variability of thromboelastographic parameters following rFVIIa in vivo administration in haemophilia patients: a randomised multi-centre trial. J Thromb Haemost 2007; 120: 808-13. (Abstract).
62. Young G, Ebbesen LS, Viuff D et al. Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: a multicentre trial. Blood Coagul Fibrinolysis 2008; 19: 276-82.
63. Rodriguez-Merchan EC, Wiedel JD, Wallney T et al. Elective orthopaedic surgery for hemophilia patients with inhibitors: new opportunities. Semin Hematol 2004; 41(Suppl. 1): 109-16.
64. Obergfell A, Auvinen M-K, Mathew P. Recombinant activated factor VII for haemophilia patients with inhibitors undergoing orthopaedic surgery: a review of the literature. Haemophilia 2008; 14: 233-41.
65. R) in elective orthopaedic surgery in haemophilic patients with inhibitors. Haemophilia 2009; 15: 501-8.
66. Schulman S, Bech Jensen M, Varon D et al. Feasibility of using recombinant factor VIIa in continuous infusion. Thromb Haemost 1996; 75: 432-6.
67. Schulman S. The onerous task of comparing treatments in inhibitor patients. Thromb Haemost 2007; 98: 710-2.
68. Pruthi RK, Mathew P, Valentino LA et al. Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Results from an open-label, randomized, multicenter trial. Thromb Haemost 2007; 98: 726-32.
69. Smith MP, Ludlam CA, Collins PW et al. Effective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII. Thromb Haemost 2001; 86: 949-53.
70. Kroner B. Comparison of the international immune tolerance registry and the North American immune tolerance registry. Vox Sang 1999; 77: 33-7.
71. Lenk H. The German registry of immune tolerance in haemophilia - 1999 update. Haematologica 2000; 85: 45-7.
72. DiMichele DM. Immune tolerance therapy for factor VIII inhibitors: moving from empiricism to an evidence-based approach. J Thromb Haemost 2007; 5(Suppl. 1): 143-50.
73. Santagostino E, Mancuso ME, Rocino A, Mancuso G, Scaraggi F, Mannucci PM. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost 2006; 4: 367-71.
74. Salaj P, Brabec P, Penka M et al. Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czeck Republic. Haemophilia 2009; 15: 752-59.
75. Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
76. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
77. Saxon BR, Shanks D, Jory CB, Williams V. Effective prophylaxis with daily recombinant factor VIIa (rFVIIa-NovoSeven) in a child with high titre inhibitors and a target joint. Thromb Haemost 2001; 86: 1126-7.
78. Young G, McDaniel M, Nugent DJ. Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors. Haemophilia 2005; 11: 203-7.
79. Morfini M, Auerswald G, Kobelt RA et al. Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European haemophilia centres. Haemophilia 2007; 13: 502-7.
80. Konkle BA, Ebbesen LS, Erhardtsen E et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5: 1904-13.
81. Hoots WK, Ebbesen LS, Konkle BA et al. Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors. Haemophilia 2008; 14: 466-75.
82. Hedner U. Potential role of recombinant factor VIIa in prophylaxis in severe hemophilia patients with inhibitors. J Thromb Haemost 2006; 4: 2498-500.
83. Almus FE, Rao LV, Fleck RA, Rapaport SI. Properties of factor VIIa/tissue factor complexes in an umbilical vein model. Blood 1990; 76: 354.
84. Hoffman M, Colina CM, McDonald AG, Arepally GM, Pedersen L, Monroe DM. Tissue factor around dermal vessels has bound factor VII in the absence of injury. J Thromb Haemost 2007; 5: 1403-8.
85. Bysted BV, Scharling B, Møller T, Hansen BL. A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25°C stable formulation. Haemophilia 2007; 13: 527-32.